Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal) in France: A National Retrospective Cross-Sectional Study (OPALE 2).

Fiche publication

Date publication

mai 2026

Journal

Substance use & addiction journal

Auteurs

Membres identifiés du Cancéropôle Est :
Pr TROJAK Benoît

Tous les auteurs :
Deschenau A, Melin P, Azuar J, Touchon B, Vinel-Jacquet I, Trojak B, Blecha L, Cabé J, Kosim M, Dupeyron G, Daulouède JP, Brousse G, Chappuy M, Rolland B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42132391

Résumé

Opioid agonist treatment (OAT) is the mainstay for opioid use disorder (OUD). Long-acting injectable buprenorphine may address limitations of daily medications by reducing treatment burden and improving engagement. This study assessed retention and patient-reported outcomes with Buvidal in France.